Karlijn De Joode

Blood-based kinase activity profiling to predict response to immune checkpoint inhibitors in patients with advanced stage NSCLC: the prospective IOpener study.

Journal: Journal for immunotherapy of cancer

Published: June 15, 2026

Response to letter Re: Impact of immune-related adverse events on quality of life and physical functioning in older patients with solid tumors treated with immune checkpoint inhibitors.

Journal: European journal of cancer (Oxford, England : 1990)

Published: September 12, 2025

Long-term survivors of melanoma after anti-PD-1 therapy demonstrate on-treatment increase in abundance of 4-1BB+ CD4 T cells in blood.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Published: July 31, 2025

The impact of immune checkpoint inhibitors on gonadal function in patients with solid tumors.

Journal: ESMO open

Published: July 25, 2025

Thromboembolism in patients with melanoma receiving immune checkpoint inhibitors: incidence and risk factors.

Journal: Immuno-oncology technology

Published: July 21, 2025

Letter Re: Patient-reported outcomes with adjuvant nivolumab versus placebo after complete resection of stage IIB/C melanoma in the randomized phase 3 CheckMate 76 K trial.

Journal: European journal of cancer (Oxford, England : 1990)

Published: May 01, 2025

Impact of geriatric impairments on outcomes of single-agent immunotherapy in solid tumors.

Journal: International journal of cancer

Published: April 16, 2025

Impact of immune-related adverse events on quality of life and physical functioning in older patients with solid tumors treated with immune checkpoint inhibitors.

Journal: European journal of cancer (Oxford, England : 1990)

Published: March 01, 2025

From decision to reflection: understanding the experiences and unmet care needs of patients treated with immunotherapy for melanoma in the adjuvant or metastatic setting.

Journal: BMC cancer

Published: April 24, 2024

Multi-omic analysis identifies hypoalbuminemia as independent biomarker of poor outcome upon PD-1 blockade in metastatic melanoma.

Journal: Scientific reports

Published: February 09, 2024

Safe Stop IPI-NIVO trial: early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab - study protocol.

Journal: BMC cancer

Published: January 30, 2024

Review - The impact of pharmacogenetics on the outcome of immune checkpoint inhibitors.

Journal: Cancer treatment reviews

Published: October 04, 2023

Blood-based kinase activity profiling to predict response to immune checkpoint inhibitors in patients with advanced stage NSCLC: the prospective IOpener study.

Blood-based kinase activity profiling to predict response to immune checkpoint inhibitors in patients with advanced stage NSCLC: the prospective IOpener study.

Response to letter Re: Impact of immune-related adverse events on quality of life and physical functioning in older patients with solid tumors treated with immune checkpoint inhibitors.

Response to letter Re: Impact of immune-related adverse events on quality of life and physical functioning in older patients with solid tumors treated with immune checkpoint inhibitors.

Long-term survivors of melanoma after anti-PD-1 therapy demonstrate on-treatment increase in abundance of 4-1BB+ CD4 T cells in blood.

Long-term survivors of melanoma after anti-PD-1 therapy demonstrate on-treatment increase in abundance of 4-1BB+ CD4 T cells in blood.

The impact of immune checkpoint inhibitors on gonadal function in patients with solid tumors.

The impact of immune checkpoint inhibitors on gonadal function in patients with solid tumors.

Thromboembolism in patients with melanoma receiving immune checkpoint inhibitors: incidence and risk factors.

Thromboembolism in patients with melanoma receiving immune checkpoint inhibitors: incidence and risk factors.

Letter Re: Patient-reported outcomes with adjuvant nivolumab versus placebo after complete resection of stage IIB/C melanoma in the randomized phase 3 CheckMate 76 K trial.

Letter Re: Patient-reported outcomes with adjuvant nivolumab versus placebo after complete resection of stage IIB/C melanoma in the randomized phase 3 CheckMate 76 K trial.

Impact of geriatric impairments on outcomes of single-agent immunotherapy in solid tumors.

Impact of geriatric impairments on outcomes of single-agent immunotherapy in solid tumors.

Impact of immune-related adverse events on quality of life and physical functioning in older patients with solid tumors treated with immune checkpoint inhibitors.

Impact of immune-related adverse events on quality of life and physical functioning in older patients with solid tumors treated with immune checkpoint inhibitors.

From decision to reflection: understanding the experiences and unmet care needs of patients treated with immunotherapy for melanoma in the adjuvant or metastatic setting.

From decision to reflection: understanding the experiences and unmet care needs of patients treated with immunotherapy for melanoma in the adjuvant or metastatic setting.

Multi-omic analysis identifies hypoalbuminemia as independent biomarker of poor outcome upon PD-1 blockade in metastatic melanoma.

Multi-omic analysis identifies hypoalbuminemia as independent biomarker of poor outcome upon PD-1 blockade in metastatic melanoma.

Safe Stop IPI-NIVO trial: early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab - study protocol.

Safe Stop IPI-NIVO trial: early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab - study protocol.

Review - The impact of pharmacogenetics on the outcome of immune checkpoint inhibitors.

Review - The impact of pharmacogenetics on the outcome of immune checkpoint inhibitors.

Letter Re: Patient-reported outcomes with adjuvant nivolumab versus placebo after complete resection of stage IIB/C melanoma in the randomized phase 3 CheckMate 76 K trial.

Letter Re: Patient-reported outcomes with adjuvant nivolumab versus placebo after complete resection of stage IIB/C melanoma in the randomized phase 3 CheckMate 76 K trial.